Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

TWi Pharma Regains US Rights to Products from Teva

publication date: Feb 24, 2015
TWi Pharma of Taiwan has reacquired US distribution rights to two of its products from Teva, which TWi will now market through its own US subsidiary. The two products are Megace® ES (megestrol acetate oral suspension), a treatment for weight loss, and Lidoderm® (lidocaine patch, 5%), a topical anesthetic. TWi makes difficult-to-make generic products, often with a controlled release delivery, with the US market as its primary target. More details....

Stock Symbols: (TW: 4180) (NYSE: TEVA)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital